Market Overview

UPDATE: BMO Capital Markets Reiterates Outperform Rating, Raises PT on Medtronic on FY3Q13 Revenue

Related MDT
Medtronic Micra TPS Meets Global Clinical Trial's Safety and Effectiveness Endpoints
13 Stocks To Watch In The Healthcare Space
Do Not Strike Stryker Out (Seeking Alpha)

In a report published Wednesday, BMO Capital Markets reiterated its Outperform rating on Medtronic (NYSE: MDT), and raised its price target from $50.00 to $52.00.

BMO Capital Markets noted, “Medtronic's FY3Q13 revenue was in line, EPS beat, and management reiterated guidance. In FY3Q13, Medtronic delivered revenue of $4.03B (up 2.8%; up 3.8% ex-fx), in line with the consensus estimate including ICD sales of $654 million that were a bit below the consensus' $668 million (we estimate MDT held share at 44.8% y/y) while other revenue components were either essentially in line or somewhat better than expected (e.g., pacemaker sales were $459 million versus consensus' $448 million). EPS of $0.93 beat our consensus-matching $0.91.”

Medtronic closed on Tuesday at $45.80.

Latest Ratings for MDT

Nov 2015Credit SuisseMaintainsOutperform
Oct 2015Evercore ISI GroupUpgradesHoldBuy
Sep 2015JefferiesMaintainsHold

View More Analyst Ratings for MDT
View the Latest Analyst Ratings

Posted-In: BMO Capital MarketsAnalyst Color Price Target Analyst Ratings


Related Articles (MDT)

View Comments and Join the Discussion!

Get Benzinga's Newsletters